Novartis insists on emergency approval of Swiss corona drug

Novartis boss Vas Narasimhan wants to step on the gas. A corona drug that was developed in cooperation with Molecular Partners AG from Schlieren ZH should be on the market earlier.

Narasimhan would like to apply to the US FDA for emergency approval, the pharmaceutical boss said in an interview with “Bloomberg”. The crux of the matter: The drug with the active ingredient Ensovibep is currently only in the second phase of approval. Large clinical studies on the results are also missing.

Share:

Facebook
Twitter
LinkedIn

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

On Key

Related Posts